Larka is pleased to announce it performed the Commercial Due Diligence for Afinum Management—supporting its acquisition of ProJect Pharmaceutics, a leading formulation development specialist for ADC, biologics and complex small molecules.

Larka is pleased to announce it performed the Commercial Due Diligence for Partners Group—supporting its acquisition of FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO).

Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Motion Equity Partners—supporting its acquisition of Banook, a leading French Central Service Provider.

Leveraging Lensource®, Larka enabled the identification and selection of CRO, CDMO and CMO partners for 4 major Biotech & Pharma clients, including...

Juvisé Pharmaceuticals leveraged Larka’s Lensource® solution for the identification, assessment and selection of a Contract Manufacturing Organisation (CMO) partner to supply one of its commercial products.

Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Biose Industrie—a world-leading Contract Development and Manufacturing Organisation (CDMO)—acquired by L-GAM & the French State.

Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Apax Partners, supporting its acquisition of Porsolt, a leading French Contract Research Organization (CRO).

Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Albumedix – a leading recombinant albumin-based solution provider based in Nottingham, UK – acquired by the Sartorius Group.

Larka is delighted to announce it acted as the buy-side Commercial Due Diligence provider to support Keensight Capital on its acquisition of a majority stake in Axxam, a global-leading Contract Research Organization (CRO) based in Italy.

Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France.

Larka provides Merieux Equity Partners with a Commercial Due Diligence to support its investment in French BioPharma company Janvier Labs.

Larka provides Elyan Partners with a Commercial Due Diligence to support the acquisition of CRO services Business Unit of Oncodesign, a leading French BioPharma company.

Larka provides Gimv with a Technical Due Diligence and Operational Due Diligence to support its investment in leading Dutch bio-CDMO BioConnection.

Fresh out of college and hired amid the COVID-19 pandemic, Yana saw in Larka an opportunity to shape a career within the BioPharma industry while evolving in a fast-paced and exciting environment.

Larka is very pleased to announce that it’s M&A Unit performed the Vendor Commercial Due-Diligence to support Afinum’s exit process of evitria, a global leading service provider specialized in transient antibody expression.

Larka is very proud to announce that it performed the Commercial-Due-Diligence for Keensight Capital on its acquisition of Symeres.

Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed - on their acquisition of Biodextris.

As a result of a strong and continued growth in recent years, we are delighted to announce the opening of our new office in Nice.

Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Cathay Capital.

Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital.

Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Archimed.

Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital and ERES, the new shareholders of Biovian.